ROIVANT SCIENCES LTD. (ROIV) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $5.13B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $701.00K; Retained Earnings (Accumulated Deficit)USD $-900.35M.
- 2026-03-31: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $5.02B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $4.36M; Retained Earnings (Accumulated Deficit)USD $-501.81M.
- 2025-12-31: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $4.94B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $20.61M; Retained Earnings (Accumulated Deficit)USD $-695.00M.
- 2025-09-30: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $4.77B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $19.56M; Retained Earnings (Accumulated Deficit)USD $-429.11M.
ROIVANT SCIENCES LTD. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Noncontrolling Interest, Increase from Subsidiary Equity Issuance USD | Noncontrolling Interest, Decrease from Deconsolidation USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $5.13B | $701.00K | $-900.35M | $4.23B | $4.92B | 3 month · $83.34M | (m) | (m) |
| 2026-03-31 | $0.00 | $5.02B | $4.36M | $-501.81M | $4.53B | $5.29B | 12 month · $346.17M | (m) | (m) |
| 2025-12-31 | $0.00 | $4.94B | $20.61M | $-695.00M | $4.27B | $4.97B | 3 month · $105.00M | (m) | (m) |
| 2025-09-30 | $0.00 | $4.77B | $19.56M | $-429.11M | $4.36B | $4.81B | 3 month · $81.82M | (m) | (m) |
| 2025-06-30 | $0.00 | $4.64B | $17.14M | $-315.59M | $4.35B | $4.82B | 3 month · $82.18M | (m) | (m) |
| 2025-03-31 | $0.00 | $4.56B | $9.44M | $116.06M | $4.69B | $5.19B | 12 month · $289.12M | (m) | 12 month · $3.71M |
| 2024-12-31 | $0.00 | $4.72B | $8.06M | $460.40M | $5.19B | $5.54B | 3 month · $83.68M | (m) | (m) |
| 2024-09-30 | $0.00 | $4.78B | $-18.04M | $395.58M | $5.15B | $5.58B | 3 month · $71.72M | (m) | (m) |
| 2024-06-30 | $0.00 | $4.78B | $-17.95M | $671.47M | $5.44B | $5.90B | 3 month · $50.24M | (m) | (m) |
| 2024-03-31 | $0.00 | $5.40B | $-4.08M | $576.17M | $5.97B | $6.45B | 12 month · $199.95M | (m) | 12 month · $35.15M |
| 2023-12-31 | $0.00 | $5.39B | $-27.78M | $727.29M | $6.09B | $6.58B | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $5.32B | $-3.07M | $-4.37B | $948.53M | $1.33B | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $4.98B | $-6.61M | $-4.06B | $910.73M | $1.33B | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $4.93B | $-2.62M | $-3.77B | $1.16B | $1.61B | (m) | 12 month · $87.50M | (m) |
| 2022-12-31 | $0.00 | $4.70B | $-729.00K | $-3.74B | $955.52M | $1.43B | (m) | 3 month · $87.50M | 3 month · $292.00K |
| 2022-09-30 | $0.00 | $4.54B | $9.09M | $-3.39B | $1.16B | $1.51B | (m) | (m) | (m) |
| 2022-06-30 | $0.00 | $4.47B | $5.02M | $-3.10B | $1.38B | $1.76B | 3 month · $72.79M | (m) | (m) |
| 2022-03-31 | $0.00 | $4.42B | $-946.00K | $-2.76B | $1.66B | $2.04B | 12 month · $564.96M | 12 month · $70.00M | (m) |
| 2021-12-31 | $0.00 | $4.36B | $-1.07M | $-2.49B | $1.87B | $2.25B | 3 month · $71.22M | (m) | (m) |
| 2021-09-30 | $0.00 | $4.25B | $1.28M | $-2.21B | $2.04B | $2.43B | 3 month · $397.31M | 3 month · $70.00M | (m) |
| 2021-06-30 | $0.00 | $3.82B | $-1.21M | $-2.00B | $1.72B | $1.96B | 3 month · $19.27M | (m) | (m) |
| 2021-03-31 | $0.00 | $3.81B | $1.45M | $-1.92B | $1.80B | $2.04B | 12 month · $84.96M | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | $2.17B | 3 month · $17.32M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $2.41B | 3 month · $13.91M | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $2.27B | 3 month · $14.28M | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $2.09B | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |